New Media Consumer Opinions – Lung Cancer is an indication-specific, series of reports that is designed to provide clients with online consumer opinions, sentiments, and attitudes about lung cancer treatment.
Introduction
Lung cancer stakeholders in the US are very active in online communities - sharing information, experiences, and emotions. This report looks at perceptions of products, treatment regimens, the disease, and quality of life issues as expressed by lung cancer stakeholders in major US online communities and forums.
Scope of This Report
- 216,489 stakeholder opinions from 15,912 unique online users
- Volume and quality of overall opinion is reviewed focusing on individual drugs
- Emotional scores are evaluated for each of the key drugs used in the treatment of lung cancer
- Specific stakeholder sentiments are compared across major drugs
Key Highlights
Within the targeted therapy category, Tarceva is the clear leader, generating 54% of all mentions. Avastin, in second place, generates 24% of the mentions.
Discussion around both chemotherapy and targeted therapy lung cancer treatment showed a marked increase beginning in 2007.
As a group, chemotherapy drugs generate a higher degree of positive sentiment than targeted therapies, which are nearly evenly split between positive and negative comments.
Reasons to Purchase
- Identify stakeholders’ perceptions of products, treatment regimens, and their experience with lung cancer.
- Evaluate product performance across a variety of emotional dimensions including perceptions of quality, effectiveness, and brand allegiance.
- Understand current trends in stakeholder thinking and identify patterns that may assist in future product development and launch strategy.
